Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.32 |
| ▸ | TEK | Q02763 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29546323 | 0.90 | DGAT1 (0.35) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL24377665 | 0.90 | DGAT1 (0.35) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL31748468 | 0.79 | DGAT1 (0.35) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL17919409 | 0.78 | NPC1 (0.32) | DGAT1NPC1MAPT | |
| SCHEMBL24377812 | 0.78 | DGAT1 (0.40) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL29546470 | 0.78 | DGAT1 (0.40) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL19249996 | 0.78 | DGAT1 (0.35) | DGAT1NPC1MAPT | |
| SCHEMBL31376396 | 0.75 | BRD4 (0.36) | DGAT1NPC1 | |
| SCHEMBL15749768 | 0.75 | BRD4 (0.36) | DGAT1NPC1 | |
| SCHEMBL31512681 | 0.75 | DGAT1 (0.38) | DGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190276450-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC. | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276450-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | PTK2B, ABL1, BTK | DGAT1 4822/4885EGFR 51/4885IGF1R 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.